71 results about "Organ specific" patented technology

The systems and methods disclosed herein are generally related to a cell culture system. More particularly, the systems and methods enable the culturing and interconnecting of a plurality of tissue types in a biomimetic environment. By culturing organ specific tissue types within a biomimetic environment and interconnecting each of the organ systems in a physiologically meaningful way, experiments can be conducted on in vitro cells that substantially mimic the responses of in vivo cell populations. In some implementations, the system is used to monitor how organ systems respond to agents such as toxins or medications. The system enables the precise and controlled delivery of these agents, which, in some implementations, enables the biomimetic dosing of drugs in humans to be mimicked.

A two-tiered classification system that can be integrated with the current algorithm used by pathologists for identification of the site of origin for ‘malignancy with unknown primary ’ is presented. In use, morphology, immunohistochemical (IHC) studies, and microarry-based top tier gene expression classifiers first subclassify cytokeratin positive carcinomas into adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma and urothelial carcinoma. Subsequently, organ-specific IHC-markers, if available, are used in conjunction with microarray-based second tier gene expression classifiers to assign the primary site of origin to the sample. This new hybrid approach combines IHC with a hierarchy of quantitative gene expression based classifiers into an algorithmic method that can assist pathologists to further refine and support their decision making process.

The present invention provides the use and composition of matter of angiogenic or other growth/cytokine factors expressed by mixtures of allogeneic human cell strains or lines of various types and stages of differentiation. Also provided are unencapsulated preparations (mixed with or applied to extracellular matrix material or synthetic biocompatible substances) for the purpose of temporary application to wounds or defects in the skin or other tissues for the restoration of blood supplying connective tissue to enable organ-specific cells to reestablish organ integrity as well as to inhibit excessive scar formation.

The present invention relates to a method and system of risk assessment, by profiling individuals to quantify radiation or agent sensitivity and risk on both organ specific and collective whole body levels, using data including demographic information, medical records, and data from embedded, mobile or fixed sensors. The risk assessment may include analytics on genetic make-up, family history, occupational history, environmental history, medical history, physical attributes, age/gender, socio-economic status, education, and health awareness. When the data is combined with actual and estimates of radiation or agent dose exposures in a geographic environment, the net result is the creation of a risk score which determines the predicted risk an individual has for developing induced mutation, organ injury, and/or cancer.

A rapid diagnosis method for organ specific disease state is based on obtaining an infrared absorbance spectra of a patient's blood at a frequency range from about 400 cm<-1 >to about 2000 cm<-1 >and further from about 3000 cm<-1 >to about 3100 cm<-1>. Comparing it with the predetermined normal infrared absorbance spectra of known healthy subjects for the presence or absence of predetermined features such as increase or decrease of infrared absorbance, peaks at particular frequencies allows for accurate diagnosis of a disease of an organ, including most major organs such as a heart, lungs, stomach, liver, kidneys, brain, etc.

The systems and methods disclosed herein are generally related to a cell culture system. More particularly, the systems and methods enable the culturing and interconnecting of a plurality of tissue types in a biomimetic environment. By culturing organ specific tissue types within a biomimetic environment and interconnecting each of the organ systems in a physiologically meaningful way, experiments can be conducted on in vitro cells that substantially mimic the responses of in vivo cell populations. In some implementations, the organ systems are fluidically connected with a constant-volume pump.

A method and system for semantic segmentation laparoscopic and endoscopic 2D/2.5D image data is disclosed. Statistical image features that integrate a 2D image channel and a 2.5D depth channel of a 2D/2.5 laparoscopic or endoscopic image are extracted for each pixel in the image. Semantic segmentation of the laparoscopic or endoscopic image is then performed using a trained classifier to classify each pixel in the image with respect to a semantic object class of a target organ based on the extracted statistical image features. Segmented image masks resulting from the semantic segmentation of multiple frames of a laparoscopic or endoscopic image sequence can be used to guide organ specific 3D stitching of the frames to generate a 3D model of the target organ.

A method and system which displays a single image after a plurality of windows have been applied to image data according to one or more organ masks. The method is accomplished by collecting a radiological scan from an imaging device to form image data; obtaining an anatomically significant mask for said image data; determining a portion of said image data as background; applying a plurality of windows to said image data determined according to said anatomically significant mask and according to said background to determine display values of said image data; and generating a generated display image from said display values.

Provided are methods of treating and/or preventing dermatological disorders. Provided are methods of reducing skin inflammation, reducing pain, and/or reducing itch in a subject in need thereof. The methods may include administering to the subject an effective amount of a TRPV4 inhibitor. Further provided are compositions including a TRPV4 inhibitor compound in combination with a carrier, vehicle, or diluent that is suitable for topical application. Further provided is a transgenic mouse whose genome includes deletions of the Trpv4 gene in keratinocytes of the epidermis, wherein said transgenic mouse is a knockout for the Trpv4 gene in keratinocytes of the epidermis following keratinocyte-specific activation and expression of a site-specific recombination enzyme.

The present invention relates to cotton tissue specific and pathogenic bacterium inducing promoter and their application, and belongs to the field of biotechnology. The promoter contains CAAT-box, TATA-box, ethylene, methyl jasmonate, abscisic acid response element, pathogenic bacterium inducer response elements W boxes, GT-1, MYB, MYBST1, MYB1LEPR, etc. There are also specific root expressing elements to enhance the expression of GUS gene, which expresses specifically in the phloem of root, bud and stem, the vein of foliage and the guard cell of air pore. Paraffin section observation shows that GHNBS promoter expresses in phloem companion cell. After treatment with SA, MeJA, Ethylene, pathogenic bacteria of blight and pseudomonas syringae DC3000, GUS will have obviously raised activity, so that it is one organ specific and pathogenic bacterium relevant promoter.

Provided are reagents and methods for non-invasive in vivo imaging wherein the reagents comprise targeted carrier molecules conjugated to a NIR reporter molecule. In one aspect the targeted carrier molecule is an antibody, or fragment thereof that has specificity for an antigen in a living body, animal or human. In one embodiment the antibodies are anti-cancer/tumor marker antibodies, organ specific antibodies, tissue specific antibodies, cell type specific antibodies, cell surface specific antibodies, anti-viral antibodies, anti-bacterial antibodies and anti-pathogenic antibodies. The NIR reporter molecules are any fluorescent reporter molecule compatible with in vivo imaging and generally having an excitation wavelength of at least 580 nm.

An imager (10) and a reconstruction processor (12) generate an intensity image (14). A region containing a target volume is identified (20) and limited (24). A classifier (30) operates on the voxels in the limited volume with an enhancement filter to generate an enhanced image, such as an image whose voxel values represent a probability that each voxel is in the target volume. A segmentation processor (40) segments the enhanced image to identify the surface of the target volume to generate a segmented image which is displayed on a monitor (52) or used in a radiation therapy planning system (54).

Methods and compositions to elicit or enhance immunity in humans against self tumor antigens are disclosed. Such immunity is generated by immunization with homologous foreign proteins. Self tumor antigens include protein expression products of overexpressed human oncogenes, such as human HER-2/neu protein, and organ-specific or tissue-specific differentiation antigens, such as PAP or PSA, associated with tumor cells.

The identification and cloning of the gene(s) for plant asparagine synthetase (AS), an important enzyme involved in the formation of asparagine, a major nitrogen transport compound of higher-plants is described. Expression vectors constructed with the AS coding-sequence may be utilized to produce plant AS; to engineer herbicide resistant plants, salt/drought tolerant plants or pathogen resistant plants; as a dominant selectable marker; or to select for novel herbicides or compounds useful as agents that synchronize plant cells in culture. The promoter for plant AS, which directs high levels of gene expression and is induced in an organ specific manner and by darkness, is also described. The AS promoter may be used to direct the expression of heterologous coding sequences in appropriate hosts.

The present invention relates generally to a method of genetic fingerprinting and more particularly to a method of establishing a methylation signature for a particular eukaryotic cell or group of cells such as in the form of tissue cells or organ-specific cells. The method of the present invention exploits the sensitivity of certain restriction enzymes to methylation. Exposure of genomic or transgene DNA to these enzymes followed by amplification results in products which establish the methylation signature or profile (i.e. the methylome profile) of a cell's or group of cells' genome when compared to the amplified genome in undigested form. The method of the present invention is useful inter alia in phenotyping a cell based on its methylation signature and provides a useful tool in functional genomics and for the design of therapeutic and trait-modifying protocols, particularly for animals and plants. The present invention can also be used to identify and map junctions between methylated and unmethylated DNA. The method of the present invention is also useful for identifying DNA methylation polymorphisms which can be used inter alia in diagnosis and forensics and for identifying particular genes, the function or absence of function of which are associated with a disease condition or trait. The method is also useful for monitoring the aging process of particular cells or an animal (including a human) or plant comprising such cells as well as monitoring the pluripotent or multipotent state of stem cells and development of stem cells through to maturation.

An agent selected from: (a) a pathogenic self-antigen associated with a T-cell-mediated specific autoimmune disease of an organ; (b) a peptide which sequence is comprised within the sequence of (a); (c) a peptide obtained by modification of (b), by replacement of one or more amino acid residues by different amino acid residues, said modified peptide still being capable of recognizing the T-cell receptor recognized by the parent peptide but with less affinity; (d) a nucleotide sequence encoding (a), (b), or (c); and (e) T cells activated by a pathogenic self-antigen of (a), a peptide of (b), or a modified peptide of (c), can be used for treatment of a non-autoimmune disease, disorder or injury in said organ. For example, uveitogenic antigens or peptides thereof can be used for treatment of a non-autoimmune disease, disorder or injury in the eye.

Provided are methods of treating and/or preventing dermatological disorders. Provided are methods of reducing skin inflammation, reducing pain, and/or reducing itch in a subject in need thereof. The methods may include administering to the subject an effective amount of a TRPA1 and/or TRPV4 inhibitor. Further provided are compositions including a TRPA1 and/or TRPV4 inhibitor compound in combination with a carrier, vehicle, or diluent that is suitable for topical application.

A method for obtaining data includes scanning an organ with an imaging system emitting X-rays and modulating the emitted X-rays with an organ specific bowtie addition.

The present invention provides a method for assessing stem cell transplant in a protein-containing sample using multi-dimensional protein separation. Such multi-dimensional separation techniques include chromatography, electrophoresis and mass spectrometry. A protein-containing sample may comprise body fluids such as blood and serum but may also include a cell, tissue or organ. Identification of a protein present in the donor and the transplant recipient but not in the recipient sample before transplant indicates that the stem cell is grafted.

An inducer of T cell apoptosis and a health food for inducing T cell apoptosis comprising as an active ingredient of a lactic acid bacterium belonging to the genus Lactobacillus or the genus Bifidobacterium are disclosed. Particularly preferred lactic acid bacteria belonging to the genus Lactobacillus or the genus Bifidobacterium are Lactobacillus acidophilus L-92 (FERM BP-4981), Lactobacillus amylovorus CP1750 (FERM BP-10532), Bifidobacterium catenulatum CP2829 (FERM BP-10533) and Bifidobacterium longum CP760 (FERM BP-10531). The inducer of T cell apoptosis of the invention is useful in the prevention and cure of a disease such as an organ-specific autoimmune disease or type I allergy.

The invention discloses a zebrafish nervous tissue-specific enhancer and cloning and application thereof and relates to the technical field of acquisition of enhancers for tissue and organ specific expressed genes. The enhancer is used for fluorescently labeling nerve cells in a zebrafish embryo development process. Sequences of the enhancer are nucleotide sequences shown in SEQ ID NO. 2. The application of the enhancer includes: developing transgenic fishes of nervous tissue-specific expressed fluorescence so as to serve for studying nerve and organ regeneration; driving specific expression of any target genes in nervous tissues so as to provide powerful tools for researchers to study development of nervous system and treatment of related diseases. The enhancer is applicable to the research on zebrafish eye development and injury regeneration processes, helps study the effect of specific genes in terms of nervous system development and controlling and provides new materials for the treatment of related diseases.